#	Pagina
attuale pagina	/open-h2020/projects/226704/index.html
-1	/open-h2020/projects/199352/index.html
-2	/open-h2020/projects/214115/index.html
-3	/open-h2020/projects/217544/index.html
-4	/open-consip/fornitori/2016/profilo-05911621000/index.html
-5	/open-consip/fornitori/2016/profilo-02103680068/index.html
-6	/open-h2020/projects/225928/index.html
-7	/open-h2020/projects/200860/deliverables.html
-8	/open-h2020/projects/227499/index.html
-9	/open-h2020/projects/194934/index.html
-10	/open-h2020/projects/211411/index.html

Opendata, web and dolomites

ISLET SIGNED

Advancing Innovative Stem Cell-based Therapy for Diabetes in Europe

Total Cost €

EC-Contrib. €

Partnership

Views

ISLET project word cloud

Explore the words cloud of the ISLET project. It provides you a very rough idea of what is the project "ISLET" about.

cell safe diabetes severe gmp clusters strategies route atmp islet healthcare plan isolated commercial t1d scalable manufacturing golden public islets experts professionally qualitative lipidomics protocols engagement hesc standard labour quantitative overcome burden therapy human cells predicting force hpsc atmps function beta transferable dual therapeutic transplantation efficacy innovative patients type generation pancreatic treatment chain standardised pluripotent economic proteomics constellation alpha stem assays scaled medicinal citizens characterisation million compliant applicable accounts source closer quality lack health rounding introduce marketing

Project "ISLET" data sheet

The following table provides information about the project.

Coordinator	KOBENHAVNS UNIVERSITET Organization address address: NORREGADE 10 city: KOBENHAVN postcode: 1165 website: www.ku.dk contact info title: n.a. name: n.a. surname: n.a. function: n.a. email: n.a. telephone: n.a. fax: n.a.
Coordinator Country	Denmark [DK]
Total cost	7˙999˙998 €
EC max contribution	7˙999˙998 € (100%)
Programme	1. H2020-EU.3.1.3. (Treating and managing disease)
Code Call	H2020-SC1-2019-Single-Stage-RTD
Funding Scheme	RIA
Starting year	2020
Duration (year-month-day)	from 2020-03-01 to 2025-02-28

Partnership

Take a look of project's partnership.

#	participants	country	role	EC contrib. [€]
1	KOBENHAVNS UNIVERSITET KOBENHAVNS UNIVERSITET Organization address address: NORREGADE 10 city: KOBENHAVN postcode: 1165 website: www.ku.dk contact info title: n.a. name: n.a. surname: n.a. function: n.a. email: n.a. telephone: n.a. fax: n.a.	DK (KOBENHAVN)	coordinator	2˙846˙198.00
2	HELMHOLTZ ZENTRUM MUENCHEN DEUTSCHES FORSCHUNGSZENTRUM FUER GESUNDHEIT UND UMWELT GMBH HELMHOLTZ ZENTRUM MUENCHEN DEUTSCHES FORSCHUNGSZENTRUM FUER GESUNDHEIT UND UMWELT GMBH Organization address address: INGOLSTADTER LANDSTRASSE 1 city: NEUHERBERG postcode: 85764 website: www.helmholtz-muenchen.de contact info title: n.a. name: n.a. surname: n.a. function: n.a. email: n.a. telephone: n.a. fax: n.a.	DE (NEUHERBERG)	participant	1˙640˙425.00
3	ACADEMISCH ZIEKENHUIS LEIDEN ACADEMISCH ZIEKENHUIS LEIDEN Organization address address: ALBINUSDREEF 2 city: LEIDEN postcode: 2333 ZA website: www.lumc.nl contact info title: n.a. name: n.a. surname: n.a. function: n.a. email: n.a. telephone: n.a. fax: n.a.	NL (LEIDEN)	participant	851˙750.00
4	INSTITUT NATIONAL DE LA SANTE ET DE LA RECHERCHE MEDICALE INSTITUT NATIONAL DE LA SANTE ET DE LA RECHERCHE MEDICALE Organization address address: RUE DE TOLBIAC 101 city: PARIS postcode: 75654 website: www.inserm.fr contact info title: n.a. name: n.a. surname: n.a. function: n.a. email: n.a. telephone: n.a. fax: n.a.	FR (PARIS)	participant	848˙750.00
5	LIPOTYPE LIPOTYPE Organization address address: TATZBERG 47 city: DRESDEN postcode: 1307 website: n.a. contact info title: n.a. name: n.a. surname: n.a. function: n.a. email: n.a. telephone: n.a. fax: n.a.	DE (DRESDEN)	participant	700˙000.00
6	KLINIKUM RECHTS DER ISAR DER TECHNISCHEN UNIVERSITAT MUNCHEN KLINIKUM RECHTS DER ISAR DER TECHNISCHEN UNIVERSITAT MUNCHEN Organization address address: ISMANINGER STRASSE 22 city: MUENCHEN postcode: 81675 website: http://www.med.tu.muenchen.de contact info title: n.a. name: n.a. surname: n.a. function: n.a. email: n.a. telephone: n.a. fax: n.a.	DE (MUENCHEN)	participant	558˙500.00
7	PANCRYOS IVS PANCRYOS IVS Organization address address: OLE MAALOES VEJ 3 city: KOBENHAVN N postcode: 2200 website: n.a. contact info title: n.a. name: n.a. surname: n.a. function: n.a. email: n.a. telephone: n.a. fax: n.a.	DK (KOBENHAVN N)	participant	350˙000.00
8	FEDERATION INTERNATIONALE DU DIABETE REGION EUROPE AISBL FEDERATION INTERNATIONALE DU DIABETE REGION EUROPE AISBL Organization address address: CHAUSSEE DE LA HULPE 166 BLOC C city: BRUXELLES postcode: 1170 website: http://www.idf-europe.org contact info title: n.a. name: n.a. surname: n.a. function: n.a. email: n.a. telephone: n.a. fax: n.a.	BE (BRUXELLES)	participant	204˙375.00

Map

Project objective

Type 1 diabetes (T1D) is one of the main health challenges, with 6 million European citizens affected. Today, T1D accounts for a severe economic burden on healthcare and labour force. To bring advanced therapy in type T1D to patients, a scalable source of pancreatic islets for transplantation is needed. The objective of the ISLET project is to build and implement a new and innovative program for the production and marketing of human pluripotent stem cell (hPSC)-derived advanced therapy medicinal products (ATMPs) for treatment of EU citizens with T1D. To achieve this, ISLET gathers a constellation of experts to establish a transferable GMP-compliant manufacturing program based on improved and standardised protocols for generation and characterisation of future ATMPs. Furthermore, to make a product closer to the “golden standard” human pancreatic islet, ISLET will develop islet-like clusters composed of isolated hPSC-derived alpha and beta-like cells, and advance strategies for safe, up-scaled production and a quantitative go/no-go assessment of therapeutic quality. Specifically, to overcome the lack of robust qualitative and quantitative assays to assess islet function, ISLET will introduce a novel quality control concept for predicting the therapeutic efficacy by quantitative proteomics and lipidomics as part of the ATMP development chain - a concept that will be widely applicable. A commercial route for exploitation of hESC-derived ATMPs for T1D treatment with EU will be developed. Finally, a professionally supported dual plan for public engagement in the fields of stem cell therapy and diabetes is rounding up the project.

Are you the coordinator (or a participant) of this project? Plaese send me more information about the "ISLET" project.

For instance: the website url (it has not provided by EU-opendata yet), the logo, a more detailed description of the project (in plain text as a rtf file or a word file), some pictures (as picture files, not embedded into any word file), twitter account, linkedin page, etc.

Send me an email (fabio@fabiodisconzi.com) and I put them in your project's page as son as possible.

Thanks. And then put a link of this page into your project's website.

The information about "ISLET" are provided by the European Opendata Portal: CORDIS opendata.